Find similar products:
The text only version may be available in large print, Braille or audio CD.
For further information call emc accessibility on
0800 198 5000.
The product code(s) for this leaflet is: PL 01502/0005R.
Glucose Intravenous Infusion BP 50% w/v
Glucose Intravenous Infusion 50% w/v
What is in this leaflet
1. What Glucose Intravenous Infusion 50% w/v is and what it is used for
2. What you need to know before you are given Glucose Intravenous Infusion 50% w/v
3. How Glucose Intravenous Infusion 50% w/v is given to you
4. Possible side effects
5. How to store Glucose Intravenous Infusion 50% w/v
6. Content of the pack and other information
Glucose Intravenous Infusion 50% w/v is a sterile solution of glucose in water and is used to:
Talk to your doctor, pharmacist or nurse before being given the infusion if you:
Patients who are acutely ill, with pain, postoperative stress, infections, burns, nervous system, heart, liver and kidney diseases and patients who are on medicines increasing the effect of vasopressin (a hormone which regulates the amount of body fluids), when given Glucose Intravenous Infusion 50% w/v, are at particular risk of developing acute hyponatraemia (abnormally low level of sodium in the blood) which can lead to encephalopathy (brain oedema).
Children, women of childbearing potential and patients with serious brain conditions like meningitis (infection of the membranes surrounding the brain) or brain injury are at particular risk of severe and life-threatening brain swelling caused by an acute decrease in blood sodium levels.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, especially the following medicines which increase the effect of vasopressin and the risk of a low sodium level (hyponatraemia):
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
You should not drive or use machinery if you are affected by the administration of Glucose Intravenous Infusion 50% w/v.
Your nurse or doctor will give you the infusion.
Your doctor will decide the correct dosage for you and how and when the infusion will be given.
Since the infusion will be given to you by a doctor or nurse, it is unlikely that you will be given too much. If you think you have been given too much, you must tell the person giving you the infusion.
Your doctor will monitor chemical and fluid balance, glucose and electrolyte levels (including sodium) in your blood before and during treatment, especially in patients with disrupted vasopressin release (a hormone which regulates the amount of body fluids) and in patients taking medicines increasing the action of vasopressin due to the risk of hyponatraemia (abnormal low sodium level in your blood).
Like all medicines, Glucose Intravenous Infusion 50% w/v can cause side effects, although not everybody gets them.
If you get any side effects, talk to your doctor, pharmacist or nurse: This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle. The expiry date refers to the last day of the month.
Your infusion will be stored at less than 25°C and protected from light. The nurse or doctor will check that the infusion is not past its expiry date before giving you the infusion.
Glucose Intravenous Infusion 50% w/v is a clear, colourless or slightly yellowish solution. It is supplied in 20 ml clear glass ampoules (10 ampoules per carton) and in a 50 ml clear glass vial packed in cartons to contain either 10 vials or 25 vials.
Not all pack sizes may be marketed.
For any information about this medicine, please contact the Marketing Authorisation Holder
This leaflet was last revised in 03/2025.
43871/43850/15/24